Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary

Monopar Therapeutics

12/08/2026 15:10

Monopar Therapeutics Inc. MNPR.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -35 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 62 cents per share. Wall Street expected results to range from -97 cents to -31 cents per share.
Reported revenue was zero​; analysts expected zero. 
Monopar Therapeutics Inc.'s reported EPS for the quarter was a loss of 62 cents​.
The company reported a quarterly loss of $5.31 million.
Monopar Therapeutics Inc. shares had risen by 23.6% this quarter and gained 75.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 22.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Monopar Therapeutics Inc. is $117.00, about 2.2% above its last closing price of $114.46
This summary was machine generated from LSEG data August 12 at 02:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.62
-0.62
Met
Mar. 31 2026 
-0.84
-0.46
Beat
Dec. 31 2025 
-0.49
-0.64
Missed
Sep. 30 2025 
-0.43
-0.48
Missed